Shortage of supply (update) Clinical Directors Medicines Information 12th January 2015 Haloperidol injection 5mg/1ml (AmCo Ltd) Description of product affected Haloperidol injection is licensed for the rapid control of the symptoms of hostility, aggression, hyperactivity, disruptive and violent behaviour, confusion, emotional withdrawal, hallucinations and delusions associated with acute and chronic schizophrenia, mania, and hypomania, and organic brain syndrome. It is also licensed for the treatment of nausea and vomiting. Update Shortages are continuing and may extend for up to 12 months. MMPS have imported haloperidol injection for use in LTHT and the Leeds Hospices. However, we do not anticipate meeting the overall demand for haloperidol injection. In view of the continuing shortage, stocks will be removed from ward/department areas and centralised in dispensary locations across the Trust. Theatre Recovery, Critical Care, and A&E will continue to hold a small emergency supply. Use of haloperidol is expected to be prioritised for the treatment of delirium and use in rapid tranquillisation. Currently, haloperidol 5mg tablets, 1.5 mg tablets and haloperidol oral liquid are available at LTHT and community pharmacies. Haloperidol 0.5mg capsules are only available at LTHT. Alternative agents and management options Haloperidol is used in a variety of clinical areas within the Trust. Below are potential alternative options for the most common uses. Responsibility for prescribing remains with the individual clinician. If unsure, please seek advice from an appropriate specialist.